CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer

Clinical trial NCT01652079 · COMPLETED

Trial details

NCT number: NCT01652079
Sponsor: Massachusetts General Hospital
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Ovarian Cancer Fallopian Tube Cancer Primary Peritoneal Cancer

Start date: 2012-04-01
Primary completion: 2018-03-01
Enrollment: 63

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.